Zolpidem Tartrate

CAS NO. 99294-93-6
Therapeutic Class: Sedative (Treatment of trouble sleeping, treatment of insomnia)
Pharmacopoeia compliance: USP/Ph.Eur

Zolpidem is a non benzodiazepine of the imidazo pyridine class. It works by increasing GABA effects in the central nervous system by binding to GABA receptors at the same location as benzodiazepines. It generally has a half-life of two to three hours. This, however, is increased in those with liver problems.

Zolpidem was approved for medical use in the United States in 1992. It became available as a generic medication in 2007. In the United States it has a monthly cost of about US$8 for immediate release and US$66 for controlled release medication, as of 2017. In that country more than 10 million prescriptions are filled a year, making it one of the most commonly used treatments for sleeping problems.